One of the biggest challenges in treating ovarian cancer is the fact that most women are not diagnosed until the cancer has already advanced and five-year survival is around 30%. By contrast, early-stage disease is highly treatable, with a survival rate of 90%.
Even if you already have cancer, you can’t let down your guard when it comes to prevention. In fact, cancer patients have even more reason to be on guard, because they usually have a higher risk for infection or developing other types of cancer.
In an effort to stop the tobacco industry from targeting younger generations, the U.S. government took aim at youth vaping early this year, banning some e-cigarette flavors — like mint and fruit flavors.
Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.
In 2019, Pamela Hershberger, PhD, came upon a stunningly significant finding in her research lab. Dr. Hershberger, Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics, says she and her team had been “studying patients with a particular type of lung cancer — EGFR mutant lung cancer — and their response to a specific class of drugs called EGFR tyrosine kinase inhibitors.